BRCA2 gene mutation in cancer

Chunbao Xie; Jiangrong Luo; Yangjun He; Lingxi Jiang; Ling Zhong; Yi Shi

doi:10.1097/MD.0000000000031705

BRCA2 gene mutation in cancer

Medicine (Baltimore). 2022 Nov 11;101(45):e31705. doi: 10.1097/MD.0000000000031705.

Authors

Chunbao Xie¹, Jiangrong Luo², Yangjun He³, Lingxi Jiang^{4

5}, Ling Zhong⁵, Yi Shi^{4

5

6}

Affiliations

¹ Department of Laboratory Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
² Department of Anesthesiology, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu, China.
³ Department of Medical Laboratory, Southwest Medical University, Luzhou, China.
⁴ Health Management Center, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
⁵ Sichuan Provincial Key Laboratory for Human Disease Gene Study and Department of Laboratory Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
⁶ Research Unit for Blindness Prevention of Chinese Academy of Medical Sciences (2019RU026), Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu, Sichuan, China.

Abstract

Breast cancer susceptibility gene 2 (BRCA2) is the main gene associated with hereditary breast cancers. However, a mutation in BRCA2 has also been found in other tumors, such as ovarian, pancreatic, thyroid, gastric, laryngeal, and prostate cancers. In this review, we discuss the biological functions of BRCA2 and the role of BRCA2 mutations in tumor progression and therapy.

Publication types

Review

MeSH terms

BRCA2 Protein / genetics
Breast Neoplasms* / genetics
Breast Neoplasms* / pathology
Female
Genes, BRCA2
Humans
Male
Mutation
Neoplasm Proteins / genetics
Ovarian Neoplasms* / genetics

Substances

BRCA2 Protein
BRCA2 protein, human
Neoplasm Proteins